Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

This application is based on the encouraging results from the Phase 3 registration clinical study GLORY-2 (NCT06164873) of mazdutide 9 mg in Chinese adults with moderate to severe obesity. The study ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Benefits of metformin outweigh risks among young people with overweight or obesity and treated with second-gen antipsychotics.

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Real-world analysis reveals that glucagon-like peptide-1 receptor agonists provide cardiovascular benefits for adults with type 2 diabetes. Glucagon-like peptide-1 receptor agonists reduce major ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Q: I’m feeling a little fuzzy-brained and am debating whether to get tested for Alzheimer’s. Do you think it’s a good idea? — ...